LifeMD Past Earnings Performance
Past criteria checks 0/6
LifeMD's earnings have been declining at an average annual rate of -25.5%, while the Healthcare Services industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 47.3% per year.
Key information
-25.5%
Earnings growth rate
-11.3%
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | 47.3% |
| Return on equity | -320.5% |
| Net Margin | -15.5% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?
Apr 25
Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely
Mar 30LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program
Mar 13LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability
Jan 22LifeMD: A GLP-1 Play With A Kicker
Jan 11Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?
Jan 05Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper
Jan 05Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?
Dec 03Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump
Apr 17Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week
Nov 17LifeMD launches at-home screening kits for breast, colon cancers
Sep 14LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M
Aug 11LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine
Jan 10LifeMD: 4 Reasons You Should Avoid This Stock
Sep 29LifeMD: Telehealth Growth Spectacular
Sep 17LifeMD: 'Actual, Hard Numbers' Keep Us Bullish
Jul 13Two class-action shareholder suits against LifeMD dropped
May 28LifeMD (LFMD) Investor Presentation - Slideshow
May 01Revenue & Expenses BreakdownBeta
How LifeMD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 153 | -24 | 137 | 6 |
| 30 Sep 23 | 136 | -32 | 127 | 5 |
| 30 Jun 23 | 129 | -33 | 123 | 4 |
| 31 Mar 23 | 123 | -39 | 125 | 4 |
| 31 Dec 22 | 119 | -49 | 131 | 3 |
| 30 Sep 22 | 118 | -55 | 136 | 2 |
| 30 Jun 22 | 112 | -61 | 137 | 2 |
| 31 Mar 22 | 104 | -64 | 134 | 1 |
| 31 Dec 21 | 93 | -62 | 125 | 1 |
| 30 Sep 21 | 78 | -75 | 131 | 1 |
| 30 Jun 21 | 64 | -85 | 129 | 1 |
| 31 Mar 21 | 51 | -73 | 106 | 1 |
| 31 Dec 20 | 37 | -63 | 85 | 0 |
| 30 Sep 20 | 28 | -32 | 48 | 0 |
| 30 Jun 20 | 20 | -9 | 21 | 0 |
| 31 Mar 20 | 14 | -5 | 14 | 0 |
| 31 Dec 19 | 12 | -3 | 12 | 0 |
| 30 Sep 19 | 11 | -3 | 10 | 0 |
| 30 Jun 19 | 10 | -3 | 10 | 0 |
| 31 Mar 19 | 9 | -3 | 9 | 0 |
| 31 Dec 18 | 8 | -2 | 8 | 0 |
| 30 Sep 18 | 6 | -2 | 7 | 0 |
| 30 Jun 18 | 6 | -2 | 6 | 0 |
| 31 Mar 18 | 5 | -1 | 5 | 0 |
| 31 Dec 17 | 4 | -1 | 4 | 0 |
| 30 Sep 17 | 5 | -2 | 4 | 0 |
| 30 Jun 17 | 3 | -1 | 5 | 0 |
| 31 Mar 17 | 4 | -2 | 5 | 0 |
| 31 Dec 16 | 5 | -1 | 4 | 0 |
| 30 Sep 16 | 5 | -1 | 4 | 0 |
| 30 Jun 16 | 4 | 0 | 2 | 0 |
| 31 Mar 16 | 3 | 0 | 1 | 0 |
| 31 Dec 15 | 1 | 0 | 1 | 0 |
| 30 Sep 15 | 1 | 0 | 1 | 0 |
| 30 Jun 15 | 1 | 0 | 1 | 0 |
| 31 Mar 15 | 1 | 0 | 1 | 0 |
| 31 Dec 14 | 1 | 0 | 1 | 0 |
| 30 Sep 14 | 1 | 0 | 1 | 0 |
| 30 Jun 14 | 1 | 0 | 1 | 0 |
| 31 Mar 14 | 1 | 0 | 1 | 0 |
| 31 Dec 13 | 1 | 0 | 1 | 0 |
| 30 Sep 13 | 1 | 0 | 1 | 0 |
| 30 Jun 13 | 1 | 0 | 1 | 0 |
Quality Earnings: LFMD is currently unprofitable.
Growing Profit Margin: LFMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LFMD is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare LFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LFMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).
Return on Equity
High ROE: LFMD has a negative Return on Equity (-320.49%), as it is currently unprofitable.